Compare AUBN & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | IBIO |
|---|---|---|
| Founded | 1907 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8M | 83.5M |
| IPO Year | 1996 | 2009 |
| Metric | AUBN | IBIO |
|---|---|---|
| Price | $26.55 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 497.0 | ★ 679.7K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | 13.66 | ★ 81.71 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $619,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.54 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $21.60 | $0.77 |
| 52 Week High | $28.88 | $3.82 |
| Indicator | AUBN | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 38.24 |
| Support Level | $25.13 | $0.98 |
| Resistance Level | $26.58 | $1.52 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 47.50 | 29.71 |
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.